A representative case of ANHL

<p>. ¹⁸F-FDG PET/CT images of a15-year-old male patient with newly diagnosed Burkitt lymphoma. Maximum-intensity-projection view (A) showing multiple hypermetabolic lesions in the gastrointestinal tract (arrows). Axial PET (B), CT (C) and fused PET/CT (D) images showing diffused and irregular thickening of gastric wall with FDG uptake (SUVmax of 18.82).</p

The results of Fisher linear classifier and Permutation for different combinations of features.

<p>Data are mean (SD); <i>P</i> (e_act), <i>P</i> (sen_act) and <i>P</i> (spec_act) representing the mean <i>p</i>-value of the permutation test for the actual classification error, sensitivity and specificity.</p

Incidence, intensity and thickness of gastric lesions in patients with PGL and AGC.

*<p>SUVmax for ANHL vs. AGC and ANHL vs. FDG-avid MALT were significantly different by ANCOVA, <i>P</i><0.05; SUVmax: maximum standardized uptake value; THKmax: maximal thickness of tumor; FDG: fluorodeoxyglucose; AGC: advanced gastric cancer; MALT: mucosa-associated lymphoid tissue; ANHL: aggressive non-Hodgkin’s lymphoma; Data are mean ± SD or number (%).</p

Comparison of PGL and AGC with representative cases.

<p>PET (left column), CT (middle column) and PET/CT fused images (right column) of a 56-year-old male with diffuse large B-cell lymphoma (A, B and C) and a 69-year-old female with poorly differentiated AGC (D, E and F), showing gastric lesions in the lesser curvature of stomach with similar thickness of the gastric wall (THKmax: 1.4 vs. 1.6 cm; arrows in B, E). However, the SUVmax was higher for PGL (SUVmax of 22.78; arrow in A) than AGC (SUVmax of 5.24; arrow in D).</p

Multimedia Mercury Recovery from Coal-Fired Power Plants Utilizing N‑Containing Conjugated Polymer Functionalized Fly Ash

To recover multimedia mercury from coal-fired power plants, a novel N-containing conjugated polymer (polyaniline and polypyrrole) functionalized fly ash was prepared, which could continuously adsorb 99.2% of gaseous Hg0 at a high space velocity of 368,500 h–1 and nearly 100% of aqueous Hg2+ in the solution pH range of 2–12. The adsorption capacities of Hg0 and Hg2+ reach 1.62 and 101.36 mg/g, respectively. Such a kind of adsorbent has good environmental applicability, i.e. good resistance to coexisting O2/NO/SO2 and coexisting Na+/K+/Ca2+/Mg2+/SO42–. This adsorbent has very low specific resistances (6 × 106–5 × 109 Ω·cm) and thus can be easily collected by an electrostatic precipitator under low-voltage (0.1–0.8 kV). The Hg-saturated adsorbent can desorb almost 100% Hg under relatively low temperature (<250 °C). Characterization and theoretical calculations reveal that conjugated-N is the critical site for adsorbing both Hg0 and Hg2+ as well as activating chlorine. Gaseous Hg0 is oxidized and adsorbed in the form of HgXClX(ad), while aqueous Hg2+ is adsorbed to form a complex with conjugated-N, and parts of Hg2+ are reduced to Hg+ by conjugated-N. This adsorbent can be easily large-scale manufactured; thus, this novel solid waste functionalization method is promising to be applied in coal-fired power plants and other Hg-involving industrial scenes

Identifying the Association of Contrast Enhancement with Vascular Endothelia Growth Factor Expression in Anaplastic Gliomas: A Volumetric Magnetic Resonance Imaging Analysis

<div><p>Contrast enhancement is a crucial radiologic feature of malignant brain tumors, which are associated with genetic changes of the tumor. The purpose of the current study was to investigate the potential relationship among tumor contrast enhancement with MR imaging, vascular endothelial growth factor (VEGF) expression, and survival outcome in anaplastic gliomas. MR images from 240 patients with histologically confirmed anaplastic gliomas were retrospectively analyzed. The volumes of T2 hyperintense, contrast enhanced regions and necrotic regions on postcontrast T1-weighted images were measured. The ratio of the enhanced volume to necrotic volume was compared between patients with high versus low levels of VEGF expression and was further used in the survival analysis. The volumetric ratio of enhancement to necrosis was significantly higher in patients with low VEGF expression than in those with high VEGF expression (Mann-Whitney, <i>p</i> = 0.009). In addition, the enhancement/necrosis ratio was identified as a significant predictor of progression-free survival (Cox regression model, <i>p</i> = 0.004) and overall survival (Cox regression model, <i>p</i> = 0.006) in the multivariate analysis. These results suggest that the volumetric ratio of enhancement to necrosis could serve as a noninvasive radiographic marker associated with VEGF expression and that this ratio is an independent predictor for progression-free survival and overall survival in patients with anaplastic gliomas.</p></div

Kaplan-Meier estimates of survivals using volumetric ratio of enhancement to necrosis.

<p>Log-rank analysis indicated (A) a significant PFS advantage (log-rank, p = 0.013) and (B) a significant OS advantage (log-rank, p = 0.001) for patients with anaplastic gliomas with a high volumetric ratio (≥ 2) of enhancement to necrosis.</p

Anatomic MR images for anaplastic gliomas with different ratios of enhancement to necrosis (≥ 2 and < 2).

<p>The areas of contrast enhancement are marked in yellow; areas of central necrosis are marked in blue; areas of T2 hyperintensity (exclusion of contrast enhancement) are marked in green.</p

Characteristics of overall patients with anaplastic gliomas.

<p>^aLEG = VEGF (-) and VEGF (+)</p><p>^bHEG = VEGF (++) and VEGF (+++)</p><p>Abbreviations: LEG, low expression group; HEG, high expression group; KPS, Karnofsky performance status score; VEGF, vascular endothelia growth factor.</p><p>Characteristics of overall patients with anaplastic gliomas.</p

Multivariate analysis of survival outcomes.

<p>^†Cox proportional hazard regression analyses.</p><p>A <i>p</i> value of 0.05 denoted significance.</p><p>Abbreviations: HR, hazard ratio; CI, confidence interval; GTR = Gross total resection; PFS, progression free survival; OS, overall survival.</p><p>Multivariate analysis of survival outcomes.</p